Axon Ventures

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Cradle Genomics, Inc. is a biotechnology company focused on advancing non-invasive prenatal testing (NIPT) through comprehensive fetal genetic analysis and pregnancy health screening solutions. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company aims to enhance the knowledge available to expectant parents. Cradle Genomics specializes in analyzing fetal cells collected during the first trimester, allowing for rapid and safe testing that poses no risk to the mother or developing fetus. By providing critical insights early in pregnancy, Cradle Genomics empowers women to make informed health decisions.

Edico Genome Inc. is a biotechnology company specializing in bioinformatics solutions for DNA analysis. Founded in 2013 and based in La Jolla, California, the company develops the DRAGEN bio-IT processor, a sequencing application-specific integrated circuit that facilitates efficient analysis of next-generation sequencing data. This platform employs a field-programmable gate array to accelerate genome pipeline algorithms, including BCL conversion, mapping, alignment, and variant calling. By integrating its technology directly into sequencing instruments and bioinformatics servers, Edico Genome enables healthcare institutions to effectively identify connections between DNA sequence variations and human diseases. In 2018, Edico Genome became a subsidiary of Illumina, Inc.

Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company's flagship product, the Obalon Balloon System, is designed to assist weight loss in obese patients through a swallowable capsule that contains an inflatable balloon. This system includes the Obalon Navigation System, which utilizes hardware and software to monitor the balloon's placement, as well as the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon post-placement. Founded in 2008, Obalon emphasizes engineering excellence and close collaboration with clinicians to create high-quality medical products aimed at improving patient outcomes. As of early 2020, the company operated three retail treatment centers in California, underscoring its commitment to providing accessible weight loss solutions.

Edico Genome Inc. is a biotechnology company specializing in bioinformatics solutions for DNA analysis. Founded in 2013 and based in La Jolla, California, the company develops the DRAGEN bio-IT processor, a sequencing application-specific integrated circuit that facilitates efficient analysis of next-generation sequencing data. This platform employs a field-programmable gate array to accelerate genome pipeline algorithms, including BCL conversion, mapping, alignment, and variant calling. By integrating its technology directly into sequencing instruments and bioinformatics servers, Edico Genome enables healthcare institutions to effectively identify connections between DNA sequence variations and human diseases. In 2018, Edico Genome became a subsidiary of Illumina, Inc.